Site Search
Displaying results 261 - 270 of 573
Resource | Fact Sheets,
Background about ART program in Nepal:
- ART was started in Nepal in February 2004 from Sukraraj Tropical and infectious Disease Hospital, Teku.
- ART is available for free of cost for all eligible people living with HIV (PLHIV).
- Currently ART is available from 65 sites in 59 districts. HIV care is available from many sites including ART sites.
- Establishment of ART dispensing centers is underway to increase accessibility of the treatment.
- National Consolidated Guideline for Treating and Preventing HIV in Nepal 2014 is the guiding document for providing HIV treatment and care in Nepal and it is being updated in Test and Treat approach.
- CD4 count service is available from 27 sites across the country.
- Viral load testing service is available from National Public Health Laboratory and is expanded to Seti Zonal Hospital, Kailali.
Resource | Publications,
With increasing global use of antiretroviral therapy (ART) to both treat and prevent HIV, and increasing global trends in HIV drug resistance ( HIVDR), efforts to improve HIV programme quality and prevent the emergence and transmission of drug-resistant HIV must be strengthened.
This global report is based on 59 countries that reported data from more than 12 000 clinics from cohorts of patients receiving ART between 2004 and 2014. The report includes the most recent clinic-level data reported to WHO in 2015 –2016 and reflects a lag due to the 12 month cohort reporting period.
Resource | Publications,
In 2000, when the International AIDS Conference was last held in Durban, South Africa, a basic antiretroviral (ARV) regimen cost over US$10,000 per person per year (PPPY), multilateral programmes funding the fight against HIV, TB, and malaria did not exist, and many donors – such as the US government – had yet to provide a single dollar for antiretroviral treatment in resource-limited countries.
In this report, we provide an update on the key facets of HIV treatment access. It includes the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line and salvage regimens, and a summary of the opportunities for – and threats to – expanding access to affordable antiretroviral therapy (ART).
Resource | Publications,
ART is being rapidly scaled up in Myanmar, led by National AIDS Programme (NAP) and supported by many partners. Decentralization of HIV care and treatment to township and peripheral levels brings services closer to where those in need reside. ART decentralization assessment conducted to 13 decentralized ART sites in March 2015 by a joint team of national and international experts.
Resource | Guidelines,
The Guidelines for the Management of Common and Opportunistic Infections among HIV-infected Infants, Children and Adolescents in Cambodia is a second edition and an important document to ensure the consistent and high quality treatment and care of HIV-infected children at all pediatric AIDS care sites in Cambodia. The guideline includes recommendations for the prevention and treatment of caring for children in Cambodia, supported by the latest information from international guidelines and primary literature.
This guideline should be used as an important tool to assist pediatricians in providing high quality and standardized treatment to HIV-infected children aged less than 15 years in Cambodia.
Resource | Publications,
This is the first global health sector strategy on viral hepatitis, a strategy that contributes to the achievement of the 2030 Agenda for Sustainable Development.
It covers the first six years of the post-2015 health agenda, 2016–2021, building on the Prevention and Control of Viral Hepatitis Infection: Framework for Global Action, and on two resolutions on viral hepatitis adopted by the World Health Assembly in 2010 and in 2014.
The strategy addresses all five hepatitis viruses (hepatitis A, B, C, D and E), with a particular focus on hepatitis B and C, owing to the relative public health burden they represent.
Resource | Publications,
Ending AIDS by 2030 is an integral part of the Sustainable Development Goals (SDGs), which were unanimously adopted by United Nations Member States in 2015. The lessons learned in responding to HIV will play an instrumental role in the success of many of the SDGs, notably SDG 3, good health and well-being, and the goals on gender equality and women’s empowerment, reduced inequalities, global partnerships and just, peaceful and inclusive societies.
Resource | Publications,
The research aimed to provide data on how stigma and discrimination create barriers to accessing services and how they impede the scaling-up of delivery of antiretroviral therapy (ART) in Papua New Guinea. Another aim was to detail the levels of stigma and discrimination faced by people living with HIV (PLHIV) in the different provinces and regions.
There are differing experiences of PLHIV based on gender, sexuality or gender identity. The research aimed to determine and understand the contributing factors to stigma and discrimination faced by PLHIV through a research project that valued differences across gender and sexuality and generated information about those different experiences.
The international Stigma Index was the tool used to identify those situations that created heightened risks for PLHIV.
Resource | Laws and Policies,
Data from the DOH - Epidemiology Bureau shows that only 44% of all people diagnosed with HIV from 2010 to 2015 were started on Anti-Retroviral Therapy (ART). Based on the 2013 external evaluation of the health sector's response to HIV in the Philippines, long turn-around time of confirmatory HIV testing is one of the identified barriers for prompt referral and management. In the interim, this memorandum shall ensure linkage to care of clients with reactive HIV screening test to immediately be assessed by treatment hubs, satellite treatment hubs and HIV primary care clinics in order to provide early treatment and management.
Resource | Publications,
In 2013, viral hepatitis was a leading cause of death worldwide (1.46 million deaths, a toll higher than that from HIV, tuberculosis or malaria, and on the increase since 1990). More than 90% of this burden is due to the sequelae of infections with the hepatitis B virus (HBV) and hepatitis C virus (HCV).
Prevention can reduce the rate of new infections, but the number of those already infected would remain high for a generation. In the absence of additional efforts, 19 million hepatitis-related deaths are anticipated from 2015 to 2030. Treatment now can prevent deaths in the short- and medium term.